Completed EARLY_PHASE1 INTERVENTIONAL 1-arm NCT05468307

A Study of GC203 TIL in Advanced Gynecologic Tumors (10hospital)

A Clinical Study of Engineered Tumor Infiltrating Lymphocytes Injection (GC203 TIL) in Patients With Advanced Gynecologic Tumors

Sponsor: Shanghai 10th People's Hospital

Conditions Advanced Gynecologic Tumors Effects of Immunotherapy TIL Engineered With Membrane-Binding Cytokine Treatment Side Effects

Interventions Membrane Bound Cytokine Modified TIL

Updated 7 times since 2022 Last updated: Dec 4, 2025 Started: Mar 10, 2022 Primary completion: Dec 30, 2024 Completion: Dec 30, 2024

This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This EARLY_PHASE1 trial investigates Advanced Gynecologic Tumors and Effects of Immunotherapy and is currently completed. Shanghai 10th People's Hospital leads this study, which shows 7 recorded versions since 2022 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

7 versions recorded

Jan 2026 — Present [monthly]

Completed EARLY_PHASE1

Status: Recruiting → Completed
Sep 2024 — Jan 2026 [monthly]

Recruiting EARLY_PHASE1
Aug 2024 — Sep 2024 [monthly]

Recruiting EARLY_PHASE1
Jul 2024 — Aug 2024 [monthly]

Recruiting EARLY_PHASE1
Oct 2023 — Jul 2024 [monthly]

Recruiting EARLY_PHASE1

▶ Show 2 earlier versions

Nov 2022 — Oct 2023 [monthly]

Recruiting EARLY_PHASE1
Sep 2022 — Nov 2022 [monthly]

Recruiting EARLY_PHASE1

First recorded

Mar 2022

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Shanghai 10th People's Hospital
Shanghai Juncell Therapeutics

Data source: Shanghai Juncell Therapeutics

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Shanghai, China